ISRCTN14583662进行中（未招募）Unknown
A randomized, single-blind, placebo-controlled study to evaluate an oral cholera vaccination with intranasal rechallenge as an adaptive immune challenge model
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent prior to any mandated procedure
- •2. Healthy male and female volunteers, 18 to 45 years of age, inclusive at screening
- •3. Body mass index (BMI) between 18 and 30 kg/m², inclusive, and with a minimum weight of 50 kg
- •4. All subjects must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment
- •5. The participant has clinical laboratory evaluations (including clinical chemistry, hematology and complete urine analysis) within the reference range for the testing laboratory, unless the results are deemed not clinically significant by the investigator
- •6. Participants who are overtly healthy as determined by medical evaluation including medical history, vital signs, physical examination, laboratory tests and ECGs at Screening and on Day -2
- •7. The participant should be able to take MMF/placebo two times per day for 6 days and to refrain from eating 2 hours before intake
- •8. Has the ability to communicate well with the Investigator in the Dutch language and is willing to comply with the study restrictions
排除标准
- •1. The participant has signs and/or symptoms of an infection 2 weeks prior to dosing, or recurrent infection, or has had an infection requiring antibiotic treatment (e.g. sepsis, pneumonia, abscess) within 42 days prior to the start of MMF/placebo administration
- •2. The participant has (a history of) autoimmune disease such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis or other immune-inflammatory disease
- •3. The participant has a history of trauma with likely damage to the spleen, or has had surgery to the spleen or splenectomy
- •4. The participant has a known immunodeficiency
- •5. Positive Hepatitis B surface antigen (HBsAg), anti-hepatitis B core, hepatitis C, or human immunodeficiency virus antibody (HIV-Ab) at screening
- •6. Serious psychiatric or medical conditions that, in the opinion of the investigator, could interfere with treatment, compliance, or the ability to give consent.
- •7. The participant has taken any over-the-counter (OTC) or any prescription medication (with the exception of paracetamol) less than 14 days or 5 half-lives (whichever is longer) prior to the first IMP dosing, and considered as relevant by the investigator
- •8. Participant has received live attenuated vaccination within 42 days prior to Screening or intends to have vaccinations during the course of the study. SARS-CoV-2 vaccinations are not allowed 1 week prior to Screening and from 2 weeks before dosing until EOS
- •9. Participant has received any investigational drug of experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to study intervention administration, or the participant was enrolled in an investigational drug or device study within 90 days prior to the first IMP dosing
- •10. The participant has a history of hypersensitivity or allergies to any drug or to any of the components of the study interventions (i.e. Dukoral oral cholera vaccination, MMF or placebo)
- •11. The participant has lost or donated more than 400 ml of blood or blood products within 90 days prior to the start of MMF or placebo treatment (Day -2) or plans to donate blood during the study
- •12. The participant has had an acute, clinically significant illness or intervention by a surgeon or dentist within 14 days prior to screening
- •13. Current (or within the past 6 months) nicotine use in excess of 5 cigarettes per day, or unable not to smoke during visits
- •14. History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 14 units of alcohol per week, drug abuse, or regular user of sedatives, hypnotics, tranquillisers, or any other addictive agent
- •15. Previous vaccination against cholera or enterotoxigenic Escherichia coli
- •16. Travel in the last 3 years to a country where cholera or enterotoxigenic E. coli is prevalent
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisEUCTR2017-002988-18-SESanofi-Aventis Recherche & Développement508
进行中（未招募）
不适用
A clinical study to evaluate the efficacy and tolerability of a novel herbal composition to relieve constipation and to improve bowel clearanceCTRI/2022/09/046036Bohan and Co
进行中（未招募）
1 期
Evaluation of the Efficacy and Safety of Sarilumab in Patients with Polymyalgia RheumaticaPolymyalgia rheumaticaEUCTR2017-002989-42-DKSanofi-Aventis Recherche & Développement500
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisEUCTR2017-002988-18-DKSanofi-Aventis Recherche & Développement508
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without STsegmentelevation - SOLSTICESubjects with myocardial infarction without ST-segment elevationMedDRA version: 9.1Level: LLTClassification code 10064347Term: Non ST segment elevation myocardial infarctionEUCTR2009-010615-32-NLGlaxoSmithKline R&D Ltd400